Business
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024 Completed two whole company acquisitions to unlock shareholder value Day One’s OJEMDA™ (tovorafenib) and Zevra’s MIPLYFFA™ (arimoclomol) each received FDA approval Cash receipts totaled $4.0 million in the fourth quarter and $46.3 million for the full year 2024 EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA),
About this update from Xoma Royalty Corporation
[{"type":"image","alt":"XOMA Royalty Corporation","displaySize":"","headline":null,"caption":"XOMA Royalty Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/19abcc56f18b6f846d93450ed04d16d8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9T1bwIBIjaqPMJV2m8ecng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/19abcc56f18b6f846d93450ed04d16d8","width":300,"height":143}},"lazy":false},{"type":"text","content":"Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024","length":141,"tagName":"p"},{"type":"text","content":"Completed two whole company acquisitions to unlock shareholder value","length":68,"tagName":"p"},{"type":"text","content":"Day One’s OJEMDA™ (tovorafenib) and Zevra’s MIPLYFFA™ (arimoclomol) each received FDA approval ","length":94,"tagName":"p"},{"type":"text","content":"Cash receipts totaled $4.0 million in the fourth quarter and $46.3 million for the full year 2024","length":97,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2024 financial results and highlighted recent activities.","length":227,"tagName":"p"},{"type":"text","content":"“Our balanced approach to building the scale of XOMA Royalty’s portfolio by selectively acquiring royalty economics across the lifecycle of drug development is beginning to bear fruit,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty. “Our growing commercial royalty portfolio of six assets is supported by VABYSMO® (faricimab), OJEMDA™, and MIPLYFFA™, while our Phase 3 portfolio, which now totals 11 assets, promises several key readouts in 2025, including ersodetug from Rezolute, seralutinib from Gossamer Bio, and Ovaprene® (non-hormonal vaginal ring) from Daré Biosciences. With over $100 million in cash on hand and a clear path to sustainable cashflow from royalties alone, we are well-positioned to further our goal of driving value for patients and shareholders alike.”","length":803,"tagName":"p"},{"type":"text","content":"Royalty and Milestone Acquisitions","length":34,"tagName":"p"},{"t...